PDCD1 and cancer: Since 2011, starting with the FDA approval of ipilimumab (an anti-CTLA4 monoclonal antibody) for immunotherapy, immune checkpoint inhibitors targeting the PD-1/PD-L1 axis were also approved to treat a broader range of cancers.